TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05259475

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle Advice
Description: Maintain a weekly healthy diet and regular exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Intervention
Description: Calorie-restricted meals (lunch and dinner)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OCFA Meal-Based Diet-Intervention
Description: OCFA-containing food product
Study: NCT06065046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 MG
Description: Baricitinib with be be administrated orally (or crushed for nasogastric tube delivery) and given daily at the dosage of 4mg for consecutive 14 days

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard treatment
Description: Patients will receive standard treatment and care according to the current management guidelines for traumatic brain injury.
Study: NCT00013052

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer led classes. Led by trained veterans with a chronic disease.
Study: NCT06002152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of 0.25% bupivacaine on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of saline on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
Study: NCT05974306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implantable loop recorder
Description: Implantation of an implantable loop recorder
Study: NCT05240144

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: IHG
Description: Isometric handgrip exercises will be performed for 4 x 2 min with the frequency of 3 days per week for a period of 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IHG
Description: Isometric handgrip exercises will be performed for 4 x 2 min with the frequency of 3 days per week for a period of 6 weeks.
Study: NCT06208072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan 150mg
Description: Irbesartan group will be treated with Irbesartan 150mg once daily for a total of 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone 25 mg
Description: Eplerenone group will be treated with Eplerenone 25mg twice daily for a total of 8 weeks
Study: NCT04773574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corneal topography, Optical coherence tomography (OCT) and Optical coherence tomography angiography (OCTA)
Description: Ocular investigations were performed in each trimesters and at 6 weeks after childbirth.~1. st trimester : gestational age 8-12 weeks~2. nd trimester : gestational age 24-28 weeks~3. rd trimester : gestational age 34-38 weeks
Study: NCT06333990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate
Description: Quetiapine is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia, bipolar disorder, and as an adjunct to treat major depression. It has a broad spectrum of actions at dopaminergic (D1, D2, D3 and D4), serotonergic (5-HT2A, 5-HT2C and 5-HT7), adrenergic (α1), histaminic (H1) and muscarinic (mACh), and partial agonist at 5-HT1A receptors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Standard of care psychotropic medications for treatment of patients with mTBI.
Study: NCT05743192

Intervention type: OTHER
Intervention: Stop performing an antibiotic susceptibility test
Description: Intervention = Stop performing an antibiotic susceptibility test for enterococcus faecalis in urine cultures. It defines two groups : one before and one after the intervention
Study: NCT05457543

Intervention type: DIAGNOSTIC_TEST
Intervention: Adult
Description: Investigational use of a novel liver function diagnostic test that involves a paper-based test device and a smartphone application.
Study: NCT05240144

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercises
Description: Aerobic exercise according to the American College of Sports Medicine (ACSM) guidelines that provide the specific criteria as 50 minutes exercises for 3 days a week for a period of 6 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aerobic exercises
Description: Aerobic exercise according to the American College of Sports Medicine (ACSM) guidelines that provide the specific criteria as 50 minutes exercises for 3 days a week for a period of 6 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham IHG
Description: Isometric handgrip exercises will be performed in 4 sets for 2 min at 5% MVC on both hands with the frequency of 3 days per week for a total 6-week period
Study: NCT04876183

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Selfapy for Binge Eating Disorder
Description: Web-based intervention for Binge Eating Disorder with six mandatory weekly sessions covering topics related to eating behaviors, emotion regulation, and stress management, followed by an optional set of up to six modular specialization areas based on individual therapy goals. During the intervention, participants can access an online chat providing crisis management, answering questions concerning the exercises, and technical support. The chat does not include the opportunity to discuss individual topics and concerns about treatment.
Study: NCT05382728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591
Description: The dose of TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo Osimertinib
Description: The dose of placebo Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT05334329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antineoplastic Immune Cell
Description: Given COH06 IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT05382728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo TY-9591
Description: The dose of placebo TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT05502289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST LENS
Description: DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST LENS
Description: DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL LENS
Description: PRECISION1™ for Astigmatism Contact Lenses (P1fA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL LENS
Description: PRECISION1™ for Astigmatism Contact Lenses (P1fA)
Study: NCT06037876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVM (200 µg/kg) + ALB (400 mg)
Description: World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected Tropical Disease (NTD) programs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALB (400mg)
Description: Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO
Study: NCT05229965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol Codeine
Description: 14 pills will be provided with a preconised dose of 1 pill 2 times per day over 7 days period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol caféine
Description: 21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
Study: NCT05278234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS
Description: Participants will initially meet with a community health worker (CHW) for a 1-hour orientation at the participant's home, a Henry Ford Health System site or the University of Michigan Detroit Center, or virtual. The CHW will show participants how to use the web modules. Participants will be given (or mailed) a wearable activity tracker to use throughout the course of the 7-week program. Each week participants will watch a brief video on the STEPS website; they may also be asked to complete handouts in the workbook. They will have a weekly 30-minute telephone session with the CHW. CHWs will review the weekly topic, help participants practice new skills, and set a related goal. CHWs will screen for social needs and make appropriate community referrals. Participants will set walking goals each week, using step-count data from the physical activity tracker. Participants will track daily step counts.
Study: NCT05021809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide intracanal medication application
Description: The patient will be anaesthized with Articaine hydrochloride 40 mg/ml + 1/100000 Epinephrine bitartrate solution . Then the rubber dam isolation will be conducted, the access will be opened and then cleaning and shaping will be done by using Protaper Next rotary file system and irrigation by sodium hypochlorite 2.5% by side vented needle, EDTA 17%, sodium hypochlorite and the final rinse by saline where the canal will be dried by absorbent paper point. The application of calcium hydroxide intracanal medication will be done according to the manufacturer instructions then temporization by glass ionomer will be applied .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide intracanal medication application
Description: The patient will be anaesthized with Articaine hydrochloride 40 mg/ml + 1/100000 Epinephrine bitartrate solution . Then the rubber dam isolation will be conducted, the access will be opened and then cleaning and shaping will be done by using Protaper Next rotary file system and irrigation by sodium hypochlorite 2.5% by side vented needle, EDTA 17%, sodium hypochlorite and the final rinse by saline where the canal will be dried by absorbent paper point. The application of calcium hydroxide intracanal medication will be done according to the manufacturer instructions then temporization by glass ionomer will be applied .
Study: NCT06152887

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sooma Oy (tDCS), Helsinki, Finland
Description: Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sooma Oy (Sham), Helsinki, Finland
Description: For the sham treatment, an electrical current will also be increased from 0 mA to 2 mA over the first 30 seconds, however, the current will be ramped back down to 0 mA after the initial ramp-up phase and no stimulation is delivered for the rest of the treatment.
Study: NCT04007276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine tartrate ophthalmic solution 0.025%
Description: Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sterile balanced saline solution
Description: Single dose of sterile balanced saline solution applied as an eye drop to the eye surface.
Study: NCT05270603

Intervention type: OTHER
Intervention: ICARUS intraoperative adverse events calculator
Description: The ICARUS calculator is a web-based tool that uses answers to Boolean, yes/no questions to determine the iAE grade (appendix I). The calculator providers iAE grade outputs for the 5 iAE classification systems.~https://garnmile.com/iaecalc/~Development of the ICARUS calculator was performed as follows: Referencing the 5 classification systems, we first assembled a list of Boolean questions based on the iAE grade descriptions. This list was distilled to the minimum number of questions necessary to represent all descriptions in the combined list of iAE grades. Next, these questions were used to independently establish the conditional logic required to determine iAE grade for each classification system. The questions and logic were translated into Hypertext Preprocessor (PHP), a server-side programming language, and JavaScript, a client-side scripting language.
Study: NCT04906915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The efficacy of ketamine was assessed by calculating oxygen supply and consumption
Study: NCT05920083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP withdrawal
Description: 2 weeks of CPAP withdrawal
Study: NCT04354454

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Participants will select a daily step goal and track their steps every day for 4.5 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit + Game + Support from a Teammate
Description: Daily Fitbit tracking for 4.5 months, divided into 2 parts.~* 3 months on active intervention with Fitbit, a Game, and Support from a self-selected Teammate and pre-designed game.~* 1.5 month follow-up period with Fitbit and social support teammate only
Study: NCT06052098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The disposable pulmonary radiofrequency ablation catheter and pulmonary radiofrequency ablation system
Description: Procedure: In combination with guided bronchoscopy and CBCT, the ablation catheter is placed in the target lesion. CBCT confirms the tool in the lesion, adjusts the position of the ablation catheter, and monitors the extent of ablation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The disposable percutaneous radiofrequency ablation needle and pulmonary radiofrequency ablation system
Description: Procedure: The ablation needle is punctured into the lesion under CT guidance. The extent of the ablation is monitored by CT.
Study: NCT06311552

Intervention type: OTHER
Intervention: Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner
Description: Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner
Study: NCT05310591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) )
Description: Patients included first receive a lympho-depleting chemotherapy by Fludarabine / Cyclophosphamide. tisagenlecleucel infusion should then be administered 2 to 14 days after completion of chemotherapy.~Nivolumab (Opdivo®) will be given intravenously at 3mg/kg every 2 weeks. It will include patients with MRD negative disease status.~1. Four decreasing starting times for beginning nivolumab (day 14, day 11, day 5 and day -1) will be available for testing~2. Patients will be enrolled sequentially by cohorts of 3 with escalation between cohorts based only on the limiting toxicities between infusion and D28~Nivolumab will be given until 12 months after tisagenlecleucel infusion in case of response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab starting at day -1
Description: It will include relapsed patients. Patients included first receive a lympho-depleting chemotherapy by Fludarabine / Cyclophosphamide. tisagenlecleucel infusion should then be administered 2 to 14 days after completion of chemotherapy.~Nivolumab (Opdivo®) will be given intravenously at 3mg/kg every 2 weeks.~-nivolumab starting at day -1.~Nivolumab will be given until 12 months after tisagenlecleucel infusion in case of response.
Study: NCT06516445

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SCRT
Description: 5×5Gy，5Gy/d，QD，D1-D5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg, D1, ivgtt, Q3W, C1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: 100mg, BID, PO, Q3W, C1-4
Study: NCT05124275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic Topical Cream, Dose 1
Description: Pilocarpine Ophthalmic Topical Cream, Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic Topical Cream, Dose 2
Description: Pilocarpine Ophthalmic Topical Cream, Dose 2
Study: NCT06516445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPEOX
Description: Capecitabine: 1000 mg/m2, BID, PO，D1-14, Q3W, C1-C4； Oxaliplatin: 130mg/m2, D1, ivgtt, 0-2h，Q3W，C1-4
Study: NCT05124275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic Topical Cream, Dose 3
Description: Pilocarpine Ophthalmic Topical Cream, Dose 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Topical Cream
Description: Placebo Ophthalmic Topical Cream
Study: NCT05478954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine
Description: Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Description: Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect. Adverse effect of amodiaquine includes abdominal discomfort and vomiting weakness and when used for prophylaxis it causes agranulocytosis. Amodiaquine is recommended as a partner drug in artemisinin based combination therapy.
Study: NCT06485115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Telerehabilitation (Euleria Home)
Description: After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the EG patients will perform the Digital Telerehabilitation program at home. The three weekly sessions will be asynchronous (with the caregiver's supervision if necessary). At each Unit, the physiotherapist will develop the training sessions on the Home- based Digital Telerehabilitation program and monitor the training execution provided by the digital device to adapt the rehabilitation treatment to the patients' improvements/difficulties. The Digital Telerehabilitation device (Euleria Home, Euleria Health) will consist of one wearable sensor and an app on a tablet that guides the patient through the customized exercise-therapy path configured by the professional. The sensor is worn on different body segments to monitor movements and provides real-time feedback on angles, balance, and repetitions.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional therapy
Description: After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the CG patients will be advised to perform the Self-management activities learned during the in-hospital rehabilitation training without home-based Digital Telerehabilitation devices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the CG patients will be advised to perform the Self-management activities learned during the in-hospital rehabilitation training without home-based Digital Telerehabilitation devices.
Study: NCT04761627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Participants will receive subcutaneous (SC) injection of ustekinumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive subcutaneous (SC) injection of ustekinumab.
Study: NCT04622995

Intervention type: DRUG
Intervention: Benzodiazepine
Description: Benzodiazepine prescribing
Study: NCT04761627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 654
Description: Participants will receive SC injection of ABP 654.